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Background: In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free
survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Here, we evaluated association of prespecified biomarkers with efficacy outcomes in LUX-H&N1.
Patients and methods: Randomized patients with R/M HNSCC and progression following2 cycles of platinum therapy
received afatinib (40mg/day) or methotrexate (40mg/m2/week). Tumor/serum samples were collected at study entry for
patients who volunteered for inclusion in biomarker analyses. Tumor biomarkers, including p16 (prespecified subgroup; all
tumor subsites), EGFR, HER2, HER3, c-MET and PTEN, were assessed using tissue microarray cores and slides; serum protein was
evaluated using the VeriStratVR test. Biomarkers were correlated with efficacy outcomes.
Results: Of 483 randomized patients, 326 (67%) were included in the biomarker analyses; baseline characteristics were
consistent with the overall study population. Median PFS favored afatinib over methotrexate in patients with p16-negative [2.7
versus 1.6months; HR 0.70 (95% CI 0.50–0.97)], EGFR-amplified [2.8 versus 1.5months; HR 0.53 (0.33–0.85)], HER3-low [2.8 versus
1.8months; HR 0.57 (0.37–0.88)], and PTEN-high [1.6 versus 1.4months; HR 0.55 (0.29–1.05)] tumors. Afatinib also improved PFS
in combined subsets of patients with p16-negative and EGFR-amplified tumors [2.7 versus 1.5months; HR 0.47 (0.28–0.80)], and
patients with p16-negative tumors who were EGFR therapy-naı¨ve [4.0 versus 2.4months; HR 0.55 (0.31–0.98)]. PFS was improved
in afatinib-treated patients who were VeriStrat ‘Good’ versus ‘Poor’ [2.7 versus 1.5months; HR 0.71 (0.49–0.94)], but no treatment
interaction was observed. Afatinib improved tumor response versus methotrexate in all subsets analyzed except for those with
p16-positive disease (n¼ 35).
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusions: Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on
prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high). Future studies are warranted to validate
these findings.
Clinical trial registration: NCT01345682.
Key words: afatinib, methotrexate, HNSCC, biomarker, phase III, EGFR
Introduction
Patients with recurrent and/or metastatic (R/M) head and neck
squamous cell carcinoma (HNSCC) who have progressed on/
after platinum-based therapy have poor prognosis and few effect-
ive treatment options. Recent clinical studies have evaluated afa-
tinib, an irreversible ErbB family blocker that inhibits signaling
from all ErbB family members [epidermal growth factor receptor
(EGFR), human EGFR 2 (HER2), HER3, HER4], in this setting
[1]. In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, afa-
tinib improved progression-free survival [PFS; median 2.6 versus
1.7months; hazard ratio (HR) 0.80; P¼ 0.030] and patient-
reported outcomes versus methotrexate as second-line treatment
of R/MHNSCC [1].
While some molecular biomarkers have been associated with
HNSCC prognosis, none are validated to predict treatment re-
sponse, particularly to EGFR-targeted therapy [2]. Dysregulation
of cell signaling factors, including EGFR- and PI3K-pathway-
related factors at the gene and/or protein level in HNSCC, has been
reported [2]. EGFR amplification has been detected in 13%–58%
of HNSCC (depending on the definition), and increased EGFR
protein expression in 90% of cases [2, 3]. There are few reports
examining other ErbB family members in HNSCC; however, stud-
ies suggest that HER3 expression is associated with poor prognosis
and resistance to EGFR-targeted therapy [4]. EGFR upregulation
was also shown to increase HER2/HER3 signaling [2]. PTENmu-
tations have been reported in 9%–23% of HNSCC, with reduced
PTEN protein expression in30% of cases [3]. In addition to their
individual correlations with HNSCC prognosis, the combined
contributions of these components within the same signaling path-
ways suggest the potential for new single-agent and combination
targeted therapies [2].
In oropharyngeal SCC (OPSCC), human papillomavirus
(HPV) infection is associated with improved prognosis in the
curative and R/M settings [5]. p16 protein is a surrogate bio-
marker for HPV infection in OPSCC (based on correlation of p16
expression with HPV status), with p16 positivity reported
in>50% of OPSCC in some countries [5]. Other molecular alter-
ations, including PI3K-pathway components, have been observed
in HPV-positive and HPV-negative HNSCC, while EGFR ampli-
fication has been exclusively associated with HPV-negative
disease [3].
Because afatinib selectively targets ErbB family signaling, as
well as the interplay between HPV, the PI3K pathway and ErbB
signaling, we were interested in whether expression of specific
biomarkers was predictive of clinical benefit with afatinib. This
study evaluates the association of prespecified biomarkers with
clinical outcomes in LUX-H&N1.
Methods
Study design and patients
LUX-H&N1 (NCT01345682) is a global, phase III trial, which enrolled
patients with second-line R/M HNSCC with progression following2
cycles of platinum therapy [1]. Patients were randomized (2 : 1) to oral
afatinib (40mg/day) or intravenous methotrexate (40mg/m2/week),
stratified by Eastern Cooperative Oncology Group performance status
(ECOG PS; 0/1) and prior EGFR-monoclonal antibody (mAb) therapy
for R/M disease. The study design and primary analysis have been re-
ported [1].
The study was conducted in accordance with the Declaration of
Helsinki and guidelines on Good Clinical Practice. The protocol was
approved by local ethics committees at each center. Written informed
consent was obtained for each patient, with separate consent obtained
from patients who volunteered for inclusion in the biomarker analysis.
Biomarker analysis
Tumor (latest obtained archived tissue) and serum samples were col-
lected from patients at study entry. Tumor biomarker assessments
included p16 (prespecified subgroup; all tumor subsites), HER2, PTEN,
c-MET and PTEN expression by immunohistochemistry, and EGFR
amplification by fluorescence in situ hybridization. Assessments were car-
ried out in a central laboratory using full, mounted tissue sections (p16
only) and tissue microarray cores (all other biomarkers). Details for each
assay are provided in supplementary Table S1, available at Annals of
Oncology online. Using a histology (H)-score of210, p16 positivity was
determined according to Ang et al. (strong, diffuse nuclear and cytoplas-
mic staining in70% of tumor cells) [6]. As there is no standard defin-
ition for EGFR amplification in HNSCC, exploratory thresholds were
defined as either extensive high-polyploidy (50% of cells with4 cop-
ies) or focal amplification (1 cell with8 copies) of the EGFR locus [7].
Similarly, as there are no established protein expression thresholds for
the other biomarkers analyzed, exploratory H-score cut-offs were used:
PTEN>150 (high), HER240 (low), HER350 (low), c-MET>75
(high). Serum samples were analyzed via the VeriStrat
VR
test (Biodesix,
Boulder, CO) [8].
Statistical analyses
Detailed statistical analyses (SAS, v9.2) for LUX-H&N1 have been pub-
lished [1]. Biomarker analyses included all randomized patients who vol-
unteered for inclusion. PFS/overall survival (OS) for each treatment
group within biomarker-defined subgroups was estimated using the
Kaplan–Meier method; HRs for afatinib versus methotrexate were
derived using a stratified Cox proportional hazards model (also used to
explore subgroup by treatment interactions). Biomarker subgroups
based on p16 and VeriStrat status were prespecified. Each biomarker sub-
group was analyzed separately; multiplicity was not adjusted.
Exploratory analyses combining prespecified subgroups and biomarkers
were also conducted. Due to the limited availability of tissue samples,
some biomarker subgroups had small sample sizes.
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Results
Patients
Of 483 randomized patients, 326 (67%) provided consent for bio-
marker analysis (supplementary Figure S1, available at Annals of
Oncology online); baseline characteristics were representative of the
overall population (supplementary Table S2, available at Annals of
Oncology online). Among patients in the tumor biomarker subset
(n¼ 268), 80% (n¼ 215) had samples from the primary tumor
site, with 14% (n¼ 37) and 4% (n¼ 11) from regional and distant
metastases (tumor site was unavailable for five patients). Among
patients with information on both timing of prior cetuximab ther-
apy for R/M disease and tumor biopsy (n¼ 139), 88% (n¼ 122)
were biopsied before cetuximab initiation.
Individual tumor biomarker analysis
Individual tumor tissue analyses yielded the following profiles for
biomarkers of interest: 85% (199/234; all tumor subsites) p16-
negative, 52% (112/214) EGFR-amplified, 55% (119/218) HER3-
low, 29% (63/221) PTEN-high, 67% (104/156) c-MET-high, and
91% (146/161) HER2-low (Table 1). Of the samples assessed for
p16 status, 34% (80/234) were OPSCC, of which the majority
(71%; 57/80) were p16-negative; 66% (154/234) were non-
OPSCC, of which 8% (12/154) were p16-positive (supplementary
Table S3, available at Annals of Oncology online). Only 9% (15/
161) of samples exhibited HER2-high expression; thus, analyses
of outcomes based onHER2 status were not conducted.
Objective response rates (ORR) were improved with afatinib
versus methotrexate in all biomarker subgroups, with the excep-
tion of patients with p16-positive disease (n¼ 35, all tumor
subsites; Table 1). Disease control rates (DCRs) were improved
with afatinib in patients with p16-negative, EGFR-amplified,
HER3-low, PTEN-high or c-MET-low disease. Notable improve-
ments in the percentage of patients experiencing Response
Evaluation Criteria In Solid Tumors (RECIST, v1.1) partial re-
sponse (i.e.>30% tumor shrinkage from baseline) with afatinib
versus methotrexate were reported in those with p16-negative
(22% versus 2%) and EGFR-amplified tumors (21% versus 0%;
supplementary Figure S2, available at Annals of Oncology online).
Improvements in median PFS were observed with afatinib
versus methotrexate in patients with p16-negative [all tumor
subsites; 2.7 versus 1.6months; HR 0.70 (95% CI 0.50–0.97)],
EGFR-amplified [2.8 versus 1.5months; HR 0.53 (0.33–0.85)], or
HER3-low [2.8 versus 1.8months; HR 0.57 (0.37–0.88)] disease,
with a trend towards improvement observed in patients with
PTEN-high tumors [1.6 versus 1.4months; HR 0.55 (0.29–1.05);
Figure 1A]. No difference in PFS between treatment groups was
observed in either c-MET subgroup. A trend toward improved
OS with afatinib was observed in patients with EGFR-amplified
[6.8 versus 4.7months; HR 0.76 (0.48–1.19)] or PTEN-high dis-
ease [7.3 versus 4.4months; HR 0.67 (0.38–1.17); Figure 1B].
Survival outcomes in patients with p16-negative or p16-positive
tumors were generally consistent when analyzed according to pri-
mary tumor site (OPSCC and non-OPSCC), with longer median
OS observed in patients with p16-positive versus p16-negative
disease, irrespective of treatment (supplementary Table S3, avail-
able atAnnals of Oncology online).
Combined tumor biomarker analysis
Because EGFR amplification has been associated with p16-
negativity in HNSCC, combined analysis of these two biomarkers
Table 1. Disposition and tumor response in biomarker-defined subgroupsa
Biomarker Biomarker subset (n5326) Tumor response: afatinib versus methotrexate
Afatinib
(n5219)
Methotrexate
(n5107)
Percentage
of total, n/N (%)b
ORR, n (%) DCR, n (%) Duration of response,
days (range)
p16-positivec 23 12 35/234 (15) 0 (0) versus 1 (8.3) 11 (47.8) versus 6 (50.0) NE versus 83
p16-negativec 135 64 199/234 (85) 19 (14.1) versus 1 (1.6) 69 (51.1) versus 23 (35.9) 91 (15–233) versus 35
EGFR amplified 83 29 112/214 (52) 11 (13.3) versus 0 (0) 43 (51.8) versus 10 (34.5) 107 (41–233) versus NE
EGFR not amplified 67 35 102/214 (48) 3 (4.5) versus 0 (0) 28 (41.8) versus 16 (45.7) 82 (43–83) versus NE
HER3 (H-score 50) 83 36 119/218 (55) 9 (10.8) versus 1 (2.8) 45 (54.2) versus 15 (41.7) 85 (36–295) versus 83
HER3 (H-score >50) 67 32 99/218 (45) 6 (9.0) versus 0 (0) 27 (40.3) versus 14 (43.8) 95 (41–197) versus NE
PTEN (H-score 150) 108 50 158/221 (71) 14 (13.0) versus 1 (2.0) 58 (53.7) versus 25 (50.0) 70 (36–295) versus 83
PTEN (H-score >150) 43 20 63/221 (29) 3 (7.0) versus 0 (0) 17 (39.5) versus 5 (25.0) 170 (82–197) versus NE
c-MET (H-score 75) 38 14 52/156 (33) 3 (7.9) versus 0 (0) 14 (36.8) versus 4 (28.6) 42 (36–170) versus NE
c-MET (H-score >75) 73 31 104/156 (67) 10 (13.7) versus 0 (0) 39 (53.4) versus 17 (54.8) 96 (41–197) versus NE
VeriStrat: good 127d 70 197/303 (65) 15 (11.8) versus 3 (4.3) 64 (50.4) versus 30 (43.5) 120 (36–295) versus 142 (83–144)
VeriStrat: poor 69 35 104/303 (34) 7 (10.0) versus 1 (2.9) 24 (34.3) versus 12 (34.3) 82 (15–113) versus 35
aIn the analysis of HER2 status, 146/161 (91%) patients were reported as HER240, and 15/161 (9%) of patients were HER2>40. Due to the small number
of patients with HER2-high expression, further outcomes analyses were not conducted.
bPercentage based on total patients with specific biomarker available.
cBased on central test results; includes tumors from all subsites (oropharyngeal and non-oropharyngeal).
dVeriStrat status was indeterminate for two patients.
DCR, disease control rate; H-score, histology-score; NE, not estimable; ORR, objective response rate.
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(all tumor subsites) was conducted. In patients with combined
p16-negative and EGFR-amplified HNSCC, significant improve-
ment in PFS with afatinib versus methotrexate was observed [2.7
versus 1.5months; HR 0.47 (0.28–0.80)], with 29% of afatinib-
treated patients achieving partial response (Table 2; supplemen-
tary Figure S3A, available at Annals of Oncology online). A trend
toward improved OS was also observed in this subset [6.8 versus
4.7months; HR 0.77 (0.47–1.26); Table 2]. No improvement in
PFS or OS was observed in the subset of patients with p16-
negative HNSCC without EGFR amplification.
In the primary analysis, improved PFS with afatinib was
observed in a prespecified subgroup of patients with p16-
negative disease and those who were EGFR mAb naı¨ve [1]. Here,
we further analyzed outcomes in a combined subset of patients
with p16-negative tumors who were also EGFR mAb naı¨ve, dem-
onstrating notable improvement in PFS [4.0 versus 2.4months;
HR 0.55 (0.31–0.98)] with afatinib versus methotrexate, with
38% of afatinib-treated patients experiencing partial response
(Table 2; supplementary Figure S3B, available at Annals of
Oncology online).
VeriStrat analysis
Of 303 patients with available serum samples, 65% were classified as
VeriStrat ‘Good’ (Table 1). VeriStrat status did not appear to impact
PFS or OS outcomes with afatinib versus methotrexate (Figure 1A
and B); however, VeriStrat was prognostic of PFS and OS in
afatinib-treated patients [PFS: 2.7 versus 1.5months; HR 0.71 (0.49–
0.94); OS: 8.8 versus 4.1months; HR 0.46 (0.33–0.64)] and OS in
methotrexate-treated patients [OS: 10.2 versus 4.4months; HR 0.40
(0.24–0.69); supplementary Figure S4, available at Annals of
Oncology online]. Consistent with the overall study results, ORRwas
improved with afatinib versus methotrexate in both VeriStrat sub-
groups; DCR was improved with afatinib in the VeriStrat ‘Good’
subgroup (Table 1). Outcomes based on VeriStrat status were inde-
pendent of other tumor biomarkers and subsite (data on file).
Biomarker
Overall study population
EGFR
Amplified
Not amplified
Low (H-score ≤50)
High (H-score >50)
Low (H-score ≤150)
High (H-score >150)
Positive (H-score ≥210)
Negative (H-score <210)
p16*
HER3
PTEN
Low (H-score ≤75)
High (H-score >75)
Good
Poor
483
112
102
119
99
158
63
35
199
52
104
197
104
2.6 vs 1.7
2.8 vs 1.5
1.6 vs 2.3
2.8 vs 1.8
1.6 vs 2.3
2.7 vs 2.4
1.6 vs 1.4
2.0 vs 2.3
2.7 vs 1.6
1.6 vs 1.5
2.8 vs 2.6
2.7 vs 2.0
1.5 vs 1.5
0.125
Favors afatinib Favors methotrexate
0.5 1 2 4 8
0.80 (0.65–0.98)
0.53 (0.33–0.85)
0.98 (0.63–1.51)
0.57 (0.37–0.88)
1.17 (0.73–1.88)
0.86 (0.60–1.28)
0.55 (0.29–1.05)
0.81 (0.39–1.69)
0.70 (0.50–0.97)
0.92 (0.46–1.84)
0.77 (0.48–1.22)
0.79 (0.56–1.08)
0.92 (0.58–1.42)
c-MET
VeriStrat
Number of patients Median PFS, months
(afatinib vs methotrexate)
HR (95% CI)
A
Figure 1. PFS (A) and OS (B) according to biomarker-defined subgroups. *Based on central test results; includes tumors from all subsites
(oropharyngeal and non-oropharyngeal). CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
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Table 2. Efficacy outcomes in combined subgroups of patients with p16-negative diseasea
p16-negative combined subgroups
EGFR amplified EGFR not amplified EGFR mAb naı¨ve EGFR mAb pretreated
Outcome Afatinib
(n562)
MTX
(n526)
Afatinib
(n549)
MTX
(n523)
Afatinib
(n551)
MTX
(n521)
Afatinib
(n584)
MTX
(n543)
Median PFS, months 2.7 1.5 1.7 2.5 4.0 2.4 1.6 1.5
HR (95% CI) 0.47 (0.28–0.80) 1.05 (0.61–1.82) 0.55 (0.31–0.98) 0.86 (0.58–1.29)
Median OS, months 6.8 4.7 5.5 6.8 8.0 10.3 6.3 5.5
HR (95% CI) 0.77 (0.47–1.26) 1.49 (0.86–2.56) 1.67 (0.92–3.02) 1.01 (0.68–1.49)
ORR, % 17.7 0 6.1 0 27.5 4.8 6.0 0
DCR, % 53.2 30.8 44.9 52.2 72.6 42.9 38.1 32.6
aData not shown in combined p16 positive subgroups due to consistently small numbers.
CI, confidence interval; DCR, disease control rate; HR, hazard ratio; mAb, monoclonal antibody; ORR, objective response rate; OS, overall survival; PFS, pro-
gression-free survival.
Biomarker
Overall study population
EGFR
Amplified
Not amplified
Low (H-score ≤50)
High (H-score >50)
Low (H-score ≤150)
High (H-score >150)
Positive (H-score ≥210)
Negative (H-score <210)
p16*
HER3
PTEN
Low (H-score ≤75)
High (H-score >75)
Good
Poor
483
112
102
119
99
158
63
35
199
52
104
197
104
6.8 vs 6.0
6.8 vs 4.7
5.5 vs 6.8
9.3 vs 6.8
5.9 vs 6.3
7.1 vs 9.0
7.3 vs 4.4
9.5 vs 13.0
6.7 vs 6.4
7.6 vs 9.0
7.8 vs 5.9
8.8 vs 10.2
4.1 vs 4.4
0.125
Favors afatinib Favors methotrexate
0.5 1 2 4 8
0.96 (0.77–1.19)
0.76 (0.48–1.19)
1.50 (0.95–2.34)
1.32 (0.84–2.07)
1.22 (0.78–1.90)
1.34 (0.93–1.92)
0.67 (0.38–1.17)
2.08 (0.87–4.99)
1.22 (0.88–1.68)
1.27 (0.64–2.52)
0.88 (0.57–1.36)
1.13 (0.80–1.60)
1.10 (0.71–1.71)
c-MET
VeriStrat
Number of patients Median OS, months
(afatinib vs methotrexate)
HR (95% CI)
B
Figure 1. Continued.
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Discussion
In this analysis of LUX-H&N1, subgroups of R/MHNSCC patients
with p16-negative, EGFR-amplified, HER3-low or PTEN-high
tumors achieved increased PFS benefit with second-line afatinib
versus methotrexate. VeriStrat appeared to be prognostic but not
predictive of differential benefit for either treatment group. In the
primary study analysis, improvement in PFS but not OS was more
pronounced with afatinib versus methotrexate in a prespecified
subgroup with p16-negative disease (HR 0.69) [1]; these findings
are consistent with results based on p16-status in the current ana-
lysis. Most samples in this study were defined as p16-negative
(85%), which is consistent with previous reports in HNSCC of
mixed primary tumor site [9]. The small number of p16-positive
samples in this study limited the statistical power of analysis in these
patients. Outcomes with EGFR mAbs in patients with HNSCC
based on p16 status have been inconclusive, with variable activity
observed with panitumumab or cetuximab plus chemotherapy,
and cetuximab plus radiotherapy in p16-negative or-positive dis-
ease [10–12]. These outcomes may have been influenced by differ-
ent definitions of p16 positivity, interactions with the combination
treatment (cytotoxic chemotherapy), differences among the EGFR
mAbs themselves, and the inherent variable activity of EGFRmAbs
against HNSCC. In analyses of patients with p16-negative HNSCC
according to prior treatment with EGFR mAb therapy, more pro-
nounced improvements in PFS and tumor response were observed
with afatinib in those who were EGFR mAb naı¨ve versus mAb pre-
treated, consistent with findings in the overall population [1].
Although a previous phase II study in R/M HNSCC suggested a
lack of cross-resistance between afatinib and cetuximab [13], the
current findings suggest that afatinib is more effective in patients
whose tumors are cetuximab naı¨ve.
More pronounced benefit with afatinib was also observed in pa-
tients with EGFR-amplified tumors, consistent with afatinib’s
mechanism of action. In previous studies, EGFR gene copy number
was not predictive of survival outcomes with gefitinibmonotherapy
or cetuximab plus chemotherapy in R/MHNSCC, although greater
response was observed with gefitinib in tumors with higher versus
lower copy number [14, 15]. These findings may reflect both the
lack of an established definition for EGFR amplification and the
generally lower activity of gefitinib in HNSCC. In lung cancer, also
characterized by EGFR gene copy number variability, amplification
is defined by either focal amplification or extensive polyploidy [7].
Adopting a similar definition here, EGFR amplification frequency
was 52%, within the range of previous reports [14, 15]. Association
of EGFR amplification with improved outcomes with afatinib may
result from afatinib’s broader mechanism of action compared with
gefitinib and cetuximab, although the impact of chemotherapy in
prior cetuximab studies should also be considered. Even more pro-
nounced improvements in PFS and tumor response were observed
with afatinib versus methotrexate in patients with combined p16-
negative and EGFR-amplified disease.
More pronounced afatinib activity was also observed in HER3-
low tumors, although three patients with HER3-high expressing
tumors did demonstrate complete responses (supplementary
Figure S2, available atAnnals of Oncology online). The implications
of this finding are not clear given the very small number of cases.
While studies suggest association between HER3 overexpression
and poor prognosis in HNSCC (including HPV-positive disease),
to our knowledge there is no evidence for HER3 as a predictive
biomarker, and a validated cut-off for HER3 overexpression has
not been established [16, 17]. We defined an exploratory H-score
of50 (membranous staining) as HER3-low, representing 55% of
samples. With more than six PI3K binding sites, HER3 is a potent
activator of the PI3K pathway; however, because HER3 is a kinase-
inactive receptor, heterodimerization with other ErbB family
members is required for signaling (supplementary Figure S5, avail-
able at Annals of Oncology online). In contrast to HER3, PTEN is a
negative regulator of the PI3K pathway, and loss of PTEN has been
associated with PI3K-pathway activation. In this analysis, 29% of
samples were identified as PTEN-high (defined as H-score>150;
cytoplasmic staining), in contrast to previous studies wherein
PTEN-low (or null) samples were reported in 30% of cases; this
is potentially due to prior exposure to cetuximab or to different
methodologies and expression thresholds (10% cut-off for PTEN-
positive stained cells [18] or automated quantitative analysis
cut-off of 570 [19]). PTEN-high expression was generally associ-
ated with poorer outcomes irrespective of treatment in this study;
however, among patients with tumors with high PTEN expression
benefit was more pronounced for those receiving afatinib ver-
sus methotrexate. More pronounced afatinib activity was
also observed in HER3-low tumors. PTEN-high and HER3-low
possibly reflect low intrinsic PI3K-pathway activity suggesting
that constitutive PI3K-pathway activation may antagonize
the activity of afatinib, although this hypothesis requires further
study.
There are some limitations to this analysis, which should be
considered. Firstly, biomarker analyses included mostly archived
tissue and, due to optional tissue/serum sampling, consisted of
67% of the study population, resulting in limited sample sizes
for some subgroups. In addition, tumor samples were collected
from both primary tumor and metastatic sites, and at different
time points relative to study entry. Furthermore, the use of tissue
microarray for analysis may not be representative of results ob-
tained from larger tissue sections. With regards to the biomarker
assessment methodology, the lack of established definitions for
gene amplification and protein expression in HNSCC resulted in
utilization of exploratory cut-offs, limiting the ability to compare
our findings with similar studies. Further, while this analysis
defined p16 status across all tumor subsites, use of p16 as a surro-
gate for HPV infection is most firmly validated in OPSCC.
In summary, this exploratory biomarker analysis of second-
line R/M HNSCC in LUX-H&N1 preliminarily identified
subgroups of patients with tumors reflecting alterations in p16
expression (p16-negative), and ErbB- and PI3K-pathway dysre-
gulation (EGFR-amplified, HER3-low, PTEN-high), who may
achieve increased benefit with afatinib versus methotrexate.
Other ErbB-targeted agents, including lapatinib (an EGFR/
HER2 inhibitor) and duligotuzumab (an EGFR/HER3 mono-
clonal antibody), have demonstrated limited activity in HNSCC
[20, 21]. Further analysis of identified subgroups may help
guide the optimal future application of these agents. Future
studies are warranted to define assessment methodologies for
these biomarkers, including relevance of the cut-offs, and pro-
vide more robust analyses of biomarker association with clinical
outcomes.
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